Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
CervoMed Inc (CRVO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.45-7.05%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CRVO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Fund operating expenses into September 2026 | The company aims to fund operating expenses into September 2026. | Intact | Funding falls short before September 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 6, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CRVO is a high-risk, loss-making clinical-stage biotechnology company, so its long-term thesis depends on turning early trial work into later-stage progress. The thesis is on watch: cash runway improved, but no partner or Phase 3 start for DLB has been reported.
The valuation evidence points to CRVO being cheap versus peers, while the expectations gap is close to neutral; model confidence is low. The priced-in assessment is justified, with no flagged fragility, but the evidence does not establish that the valuation fully reflects the company’s development and funding risks.
Near term, reported cash and marketable securities reached about $24.9 million at June 30, 2026, with management stating that planned needs are funded through the third quarter of 2027. The nfvPPA Phase 2a trial completed enrollment of 25 participants and reported early biomarker results, while a DLB partnership and Phase 3 progress remain unreported. Results are mixed, and the next update carries meaningful risk given the company’s size and the evidence of recent performance below its industry cohort.
The multi-year thesis hinges on securing a partner to advance neflamapimod into Phase 3 for DLB and on whether further nfvPPA data support continued development. Near term, a guidance cut or weakening jobs data could weigh on confidence, while stronger earnings and guidance from healthcare sector bellwethers could support sector momentum.
Over the next one to three years, CRVO’s thesis has improved funding visibility and some trial progress, but remains dependent on partnership execution and stronger clinical evidence. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| CervoMed plans to start a Phase 3 trial for neflamapimod in H2 2026. |
| Intact |
| Phase 3 trial not started by end of 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue decline limited to less than 50% next year | A supporting condition in CervoMed Inc's published investment case. The stated target is Revenue decline less than 50% in FY 2026. | Broken | Revenue falls more than 50% in FY 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.38 → $-1.48 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.38 | $833,333 | 4 / 5 |
| 2026-07-25 | $-2.38 | $833,333 | 4 / 5 |
| 2026-07-26 | $-2.38 | $833,333 | 4 / 5 |
| 2026-07-27 | $-2.38 | $833,333 | 4 / 5 |
| 2026-07-28 | $-2.38 | $833,333 | 4 / 5 |
| 2026-07-29 | $-2.38 | $833,333 | 4 / 5 |
| 2026-07-30 | $-2.38 | $833,333 | 4 / 5 |
| 2026-07-31 | $-2.32 | $714,290 | 5 / 7 |
| 2026-08-01 | $-2.38 | $833,333 | 4 / 5 |
| 2026-08-02 | $-2.50 | $833,330 | 4 / 6 |
| 2026-08-03 | $-2.50 | $833,330 | 4 / 6 |
| 2026-08-04 | $-2.54 | $1,000,000 | 4 / 4 |
| 2026-08-05 | $-2.54 | $1,000,000 | 4 / 4 |
| 2026-08-06 | $-2.50 | $833,330 | 4 / 6 |
| 2026-08-07 | $-2.54 | $1,000,000 | 4 / 4 |
| 2026-08-08 | $-2.50 | $833,330 | 4 / 6 |
| 2026-08-09 | $-2.50 | $833,330 | 4 / 6 |
| 2026-08-10 | $-2.50 | $833,330 | 4 / 6 |
| 2026-08-11 | $-2.54 | $1,000,000 | 4 / 4 |
| 2026-08-12 | $-1.81 | $1,250,000 | 3 / 4 |
| 2026-08-13 | $-1.81 | $1,250,000 | 3 / 4 |
| 2026-08-14 | $-2.54 | $1,000,000 | 4 / 4 |
| 2026-08-15 | $-2.54 | $1,000,000 | 3 / 4 |
| 2026-08-16 | $-2.54 | $1,000,000 | 3 / 4 |
| 2026-08-17 | $-2.54 | $1,000,000 | 3 / 4 |
| 2026-08-18 | $-2.54 | $1,000,000 | 4 / 4 |
| 2026-08-19 | $-2.54 | $1,000,000 | 4 / 4 |
| 2026-08-20 | $-1.50 | $1,000,000 | 4 / 4 |
| 2026-08-21 | $-1.50 | $1,000,000 | 4 / 4 |
| 2026-08-22 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-08-23 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-08-24 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-08-25 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-08-26 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-08-27 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-08-28 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-08-29 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-08-30 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-08-31 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-01 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-02 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-03 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-04 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-05 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-06 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-07 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-08 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-09 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-10 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-11 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-12 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-13 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-14 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-15 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-16 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-17 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-18 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-19 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-20 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-21 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-22 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-23 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-24 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-25 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-26 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-27 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-28 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-29 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-09-30 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-01 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-02 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-03 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-04 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-05 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-06 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-07 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-08 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-09 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-10 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-11 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-12 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-13 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-14 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-15 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-16 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-17 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-18 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-19 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-20 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-21 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-22 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-23 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-24 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-25 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-26 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-27 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-28 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-29 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-30 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-10-31 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-11-01 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-11-02 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-11-03 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-11-04 | $-1.48 | $1,000,000 | 4 / 4 |
| 2026-11-05 | $-1.48 | $1,000,000 | 4 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.